FDA Inspection 1257425 — Dilawar Ajani, M.D., P.I.
The FDA completed an inspection of Dilawar Ajani, M.D., P.I. on December 16, 2024 in Houston, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 16, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Houston, TX (United States)
Additional Details
Clinical Investigator (CI)